At the heart of scientific advances

In 2019 and 2020, the CEC was the first center to offer a GnRH antagonist, linzagolix, in clinical trials published in 2021 and 2022. This drug led to a significant reduction in adenomyosis symptoms as well as in uterine volume.

Today, we are proud to present our post-treatment findings as we look toward new clinical trials.